Login to Your Account



Alvimopan Misses Endpoint In Pivotal European Phase III

By Karen Pihl-Carey


Monday, December 27, 2004
Adolor Corp. reported topline results from a Phase III study showing its postoperative ileus drug, alvimopan, failed to meet the primary endpoint in a trial meant to support a marketing authorization application in the European Union. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription